Volunteers Needed for Medication Study to Improve Control of Type 2 Diabetes

AMCR Institute is recruiting volunteers for an important clinical trial on a new medication to treat type 2 diabetes
April 23, 2012 - PRLog -- AMCR Institute, with clinics in Escondido and Temecula, California, is recruiting volunteers to participate in an important clinical trial on a new medication to treat type 2 diabetes.
    Dr. Timothy Bailey, MD, the Institute’s director, said, “Type 2 diabetes is a serious condition that can affect the heart, eyes, nervous system and kidneys if blood sugar is not properly controlled.  This study is targeted at people currently taking metformin and offers a free trial of an investigational medication that may better control blood sugar levels and produce better patient outcomes when taken along with metformin.”
   Participants must be 18 or older and be taking oral metformin to treat their type 2 diabetes.  Qualified participants will receive study-related doctor’s visits and evaluations and study medication at no cost, and may be compensated for their time and travel.  Because the treatment is free, participants do not need medical insurance to qualify.
   For more information or to volunteer for this study, contact AMCR Institute at 877-567-2627 or visit their website at http://www.amcrinstitute.com, which is available in both English and Spanish.

With clinics in Escondido and Temecula, California, AMCR Institute is a clinical research center engaged in trials in the field of endocrinology and metabolism, focusing on type 1 and type 2 diabetes, lipids, and men’s and women’s health issues, including menopause, osteoporosis, obesity and thyroid disease.
Source:AMCR Institute
Email:***@amcrinstitute.com Email Verified
Tags:Amcr Institute, Dr. Timothy Bailey, Type 2 diabetes medication, Metformin, Escondido, Temecula
Location:Escondido - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Peoples & Company News
Daily News
Weekly News

Like PRLog?
Click to Share